88 related articles for article (PubMed ID: 17764940)
1. The evolution of treatment strategies: aiming at the target.
Dinh P; Sotiriou C; Piccart MJ
Breast; 2007 Dec; 16 Suppl 2():S10-6. PubMed ID: 17764940
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
3. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
5. [The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer].
Klijn JG; de Vries EG
Ned Tijdschr Geneeskd; 2005 Mar; 149(12):618-22. PubMed ID: 15813427
[TBL] [Abstract][Full Text] [Related]
6. What can be expected from the next generation of adjuvant breast cancer treatment?
Piccart-Gebhart M
Semin Oncol; 1999 Feb; 26(1 Suppl 3):22-5. PubMed ID: 10203267
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer chemotherapy.
McArthur HL; Hudis CA
Cancer J; 2007; 13(3):141-7. PubMed ID: 17620762
[TBL] [Abstract][Full Text] [Related]
8. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
Petrelli F; Cabiddu M; Ghilardi M; Barni S
Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
[TBL] [Abstract][Full Text] [Related]
9. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
10. [Early-stage breast cancer - strategies for adjuvant systemic therapy].
Görner M; Just M; Gerull S
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):230-8. PubMed ID: 18716990
[TBL] [Abstract][Full Text] [Related]
11. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
12. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.
Cappelletti V; Gariboldi M; De Cecco L; Toffanin S; Reid JF; Lusa L; Bajetta E; Celio L; Greco M; Fabbri A; Pierotti MA; Daidone MG
Endocr Relat Cancer; 2008 Jun; 15(2):439-49. PubMed ID: 18508997
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer.
Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
[TBL] [Abstract][Full Text] [Related]
14. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
15. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
16. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
Tsakonas G; Kosmas C
J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J; Gralow JR
Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
[TBL] [Abstract][Full Text] [Related]
18. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Del Mastro L; Clavarezza M; Venturini M
Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
